Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury.

Acute Kidney Injury / drug therapy Dopamine Agonists / therapeutic use Fenoldopam / therapeutic use Humans Kidney / drug effects Male Receptors, Dopamine D1 / agonists Treatment Outcome
DA-1 receptor Fenoldopam mesylate Intensive care unit-acute kidney injury chronic kidney disease contrast-induced nephropathy dopamine post-operative acute kidney injury.

Journal

Current pharmaceutical biotechnology
ISSN: 1873-4316
Titre abrégé: Curr Pharm Biotechnol
Pays: Netherlands
ID NLM: 100960530

Informations de publication

Date de publication:
2019
Historique:
received: 09 11 2018
revised: 04 01 2019
accepted: 08 04 2019
pubmed: 1 5 2019
medline: 8 10 2019
entrez: 1 5 2019
Statut: ppublish

Résumé

Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated. We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy. Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples. Conflicting results were achieved in contrast-induced nephropathy.

Sections du résumé

BACKGROUND BACKGROUND
Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.
METHODS METHODS
We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy.
RESULTS RESULTS
Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples.
CONCLUSION CONCLUSIONS
Conflicting results were achieved in contrast-induced nephropathy.

Identifiants

DOI: 10.2174/1389201020666190417124711 PMID: 31038062 PMC: PMC6751352
pubmed: 31038062
pii: CPB-EPUB-98135
doi: 10.2174/1389201020666190417124711
pmc: PMC6751352
doi:

Substances chimiques

DRD1 protein, human 0
Dopamine Agonists 0
Receptors, Dopamine D1 0
Fenoldopam INU8H2KAWG

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

366-375

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

Anesth Analg. 2004 Dec;99(6):1604-9, table of contents
pubmed: 15562040
Int Immunopharmacol. 2005 Jan;5(1):85-92
pubmed: 15589464
Am J Hypertens. 1990 Jun;3(6 Pt 2):59S-63S
pubmed: 1974444
Lancet. 2000 Dec 23-30;356(9248):2139-43
pubmed: 11191541
Ann Thorac Surg. 2004 Oct;78(4):1332-7; discussion 1337-8
pubmed: 15464494
Catheter Cardiovasc Interv. 2002 Nov;57(3):279-83
pubmed: 12410497
Catheter Cardiovasc Interv. 2001 Jul;53(3):341-5
pubmed: 11458411
Am J Kidney Dis. 2005 Jul;46(1):26-34
pubmed: 15983954
Am J Kidney Dis. 2017 Jan;69(1):69-77
pubmed: 27707552
Minerva Anestesiol. 2015 Jun;81(6):684-96
pubmed: 25057935
Clin Biochem Rev. 2016 May;37(2):85-98
pubmed: 28303073
Minerva Anestesiol. 2010 Apr;76(4):249-59
pubmed: 20332738
Crit Care Med. 2005 Nov;33(11):2451-6
pubmed: 16276165
Kidney Int. 2015 Nov;88(5):950-7
pubmed: 26221752
Eur J Anaesthesiol. 2002 Jan;19(1):32-9
pubmed: 11913801
J Cardiovasc Pharmacol Ther. 2001 Jan;6(1):31-6
pubmed: 11452334
Crit Care. 2015 Dec 25;19:449
pubmed: 26703329
Am J Cardiol. 2002 Apr 15;89(8):999-1002
pubmed: 11950448
Liver Transpl. 2004 Aug;10(8):986-92
pubmed: 15390323
Crit Care Med. 2006 Mar;34(3):707-14
pubmed: 16505657
Am J Physiol. 1990 Aug;259(2 Pt 2):F297-303
pubmed: 1974737
Anaesthesia. 2001 Oct;56(10):953-60
pubmed: 11576097
J Cardiothorac Vasc Anesth. 2008 Feb;22(1):23-6
pubmed: 18249326
J Clin Invest. 1973 Jan;52(1):190-7
pubmed: 4682382
J Auton Pharmacol. 1982 Sep;2(3):189-215
pubmed: 6754737
Am J Kidney Dis. 2007 Jan;49(1):56-68
pubmed: 17185146
Circulation. 2005 Jun 21;111(24):3230-5
pubmed: 15967861
J Med Chem. 1980 Sep;23(9):973-5
pubmed: 7411552
J Cardiothorac Vasc Anesth. 2003 Aug;17(4):491-4
pubmed: 12968238
Intensive Care Med. 2002 Jul;28(7):877-83
pubmed: 12122525
Medicine (Baltimore). 2018 Sep;97(38):e12465
pubmed: 30235738
J Clin Endocrinol Metab. 1988 Mar;66(3):518-25
pubmed: 2895118
Urology. 2013 Feb;81(2):340-5
pubmed: 23374797
Anesth Analg. 2006 Oct;103(4):833-40
pubmed: 17000789
Clin Imaging. 2015 Sep-Oct;39(5):759-64
pubmed: 25709111
Crit Care Med. 2001 Aug;29(8):1526-31
pubmed: 11505120
JAMA. 2014 Dec 3;312(21):2244-53
pubmed: 25265449
J Cardiothorac Vasc Anesth. 2012 Jun;26(3):407-13
pubmed: 22459931
Ann Intern Med. 2008 Feb 19;148(4):284-94
pubmed: 18283206
J Ocul Pharmacol Ther. 1998 Jun;14(3):203-16
pubmed: 9671428
Cardiovasc Ther. 2011 Aug;29(4):280-4
pubmed: 20955210
J Cardiothorac Vasc Anesth. 2007 Dec;21(6):847-50
pubmed: 18068064
JAMA. 2003 Nov 5;290(17):2284-91
pubmed: 14600187
Annu Rev Biochem. 1991;60:653-88
pubmed: 1652922
Crit Care Med. 1999 Sep;27(9):1832-7
pubmed: 10507606
Korean J Anesthesiol. 2017 Jun;70(3):258-266
pubmed: 28580076
Am J Med. 1984 Oct 5;77(4A):37-44
pubmed: 6148892
Nephrol Dial Transplant. 2004 Jul;19(7):1803-7
pubmed: 15128882
Crit Care Med. 2008 May;36(5):1427-35
pubmed: 18434903
Drugs. 1997 Oct;54(4):634-50
pubmed: 9339965
J Nephrol. 2018 Dec;31(6):797-812
pubmed: 29802583
Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2798-801
pubmed: 1849276
J Pharmacol Exp Ther. 1982 Nov;223(2):305-13
pubmed: 6127401
Catheter Cardiovasc Interv. 2002 Feb;55(2):169-73
pubmed: 11835641
N Engl J Med. 2001 Nov 22;345(21):1548-57
pubmed: 11794223
J Nephrol. 2019 Feb;32(1):75-81
pubmed: 29766465
Kidney Int. 1999 Jul;56(1):206-10
pubmed: 10411694
Am Heart J. 2002 May;143(5):894-903
pubmed: 12040355
J Am Coll Cardiol. 2004 Aug 18;44(4):762-5
pubmed: 15312855
J Intensive Care Med. 2005 Jul-Aug;20(4):199-211
pubmed: 16061903
Int J Cardiol. 2006 May 24;109(3):322-8
pubmed: 16039733

Auteurs

Annalisa Noce (A)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.

Giulia Marrone (G)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.
PhD School of Applied Medical-Surgical Sciences, Tor Vergata University, Rome, Italy.

Valentina Rovella (V)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.

Andrea Busca (A)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.

Caterina Gola (C)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.

Michele Ferrannini (M)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.

Nicola Di Daniele (N)

Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Insuffisance rénale › Atteinte rénale aigüe › Fenoldopam Mesylate: A Narrative Review of Its...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents dopaminergiques › Agonistes de la dopamine › Fenoldopam Mesylate: A Narrative Review of Its...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzazépines › Fénoldopam › Fenoldopam Mesylate: A Narrative Review of Its...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fenoldopam Mesylate: A Narrative Review of Its...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Fenoldopam Mesylate: A Narrative Review of Its...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur dopamine D1 › Fenoldopam Mesylate: A Narrative Review of Its...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Fenoldopam Mesylate: A Narrative Review of Its...